Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Harrow Health Inc (HROW)
NASDAQ:HROW
Holding HROW?
Track your performance easily
HROW Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.60 - $47.55
Previous Close$46.47
Volume695.60K
Average Volume (3M)557.51K
Market Cap
$1.65B
Enterprise Value$1.77B
Total Cash (Recent Filing)$70.97M
Total Debt (Recent Filing)$192.33M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Nov 11, 2024EPS Estimate
-$0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding35,482,944
10 Day Avg. Volume344,767
30 Day Avg. Volume557,508
Standard Deviation0.21
R-Squared0.03
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)28.16
Price to Sales (P/S)13.66
Price to Cash Flow (P/CF)-146.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue11.70
Enterprise Value/Gross Profit19.55
Enterprise Value/Ebitda286.58
Forecast
1Y Price Target
$47.50Price Target Upside5.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Harrow Health News
PremiumCompany Announcements
Harrow Health Unveils Performance Strategy to Investors
PremiumPre-Earnings
Is HROW a Buy, Before Earnings?Bulls Say, Bears Say
Bulls Say
Market ExpansionIHEEZO is moving into yet another new market with the contract agreement with Apexus, the HRSA-designated Prime Vendor for the 340B Drug Pricing Program.
Product LaunchThe exceptional launch performance of MIEBO has driven the company's decision to raise FY24 MIEBO sales guidance from $95M to $150M-$160M.
Sales GrowthBB/Symphony VEVYE-specific prescription volume data indicate ~400% q/q growth, indicative of sustained momentum.
Bears Say
Financial PerformanceInvestment-heavy market redevelopment phase could maintain choppiness in short-term product revenue and cash flow positivity.
Product LaunchUncertainty remains due to early stage of product launch and impact of free drug sampling.
Product Segment RevenueInvestment-heavy market re-development phase could maintain choppiness to product segment revenue and cash flow positivity metrics.
---
Ownership Overview
22.48% Insiders
15.50% Mutual Funds
37.03% Other Institutional Investors
24.99% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HROW FAQ
What was Harrow Health Inc’s price range in the past 12 months?
Harrow Health Inc lowest stock price was $7.60 and its highest was $47.55 in the past 12 months.
What is Harrow Health Inc’s market cap?
Currently, no data Available
When is Harrow Health Inc’s upcoming earnings report date?
Harrow Health Inc’s upcoming earnings report date is Nov 11, 2024 which is in 51 days.
How were Harrow Health Inc’s earnings last quarter?
Harrow Health Inc released its earnings results on Aug 07, 2024. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.183 by $0.003.
Is Harrow Health Inc overvalued?
According to Wall Street analysts Harrow Health Inc’s price is currently Undervalued.
Does Harrow Health Inc pay dividends?
Harrow Health Inc does not currently pay dividends.
What is Harrow Health Inc’s EPS estimate?
Harrow Health Inc’s EPS estimate is -$0.05.
How many shares outstanding does Harrow Health Inc have?
Harrow Health Inc has 35,482,944 shares outstanding.
What happened to Harrow Health Inc’s price movement after its last earnings report?
Harrow Health Inc reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.183. Following the earnings report the stock price went up 54.322%.
Which hedge fund is a major shareholder of Harrow Health Inc?
Among the largest hedge funds holding Harrow Health Inc’s share is Private Capital Management, LLC. It holds Harrow Health Inc’s shares valued at 57M.
---
Harrow Health Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.50 (5.51% Upside)
$47.50 (5.51% Upside)
Blogger Sentiment
Bullish
HROW Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 58.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 4.7%
Last 30 Days ▲ 8.7%
Last 30 Days ▲ 8.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
217.85%
12-Months-Change
Fundamentals
Return on Equity
-83.44%
Trailing 12-Months
Asset Growth
36.69%
Trailing 12-Months
Company Description
Harrow Health Inc
Harrow Health Inc is an ophthalmology-focused pharmaceutical company. The company is specialized in the development, production, and sale of medications that offer competitive advantages and serve unmet needs in the marketplace. Its cornerstone of ophthalmology program consists of proprietary Dropless Therapy injectable and LessDrops topical formulations that are designed to address patient compliance issues and provide other compelling medical and economic benefits.
---
HROW Company Deck
---
HROW Earnings Call
Q2 2024
0:00 / 0:00
---
HROW Stock 12 Month Forecast
Average Price Target
$47.50
▲(5.51% Upside)
Technical Analysis
Best Analysts Covering HROW
1 Year
1 Year Success Rate
11/12 ratings generated profit
1 Year Average Return
+195.34%
reiterated a buy rating 23 days ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +195.34% per trade.
---